MITPF Quote, Financials, Valuation and Earnings

Galapagos NV has a net margin of -- compared to Mithra Pharmaceuticals SA's net margin of -84.26%. Mithra Pharmaceuticals SA's return on equity of -- beat Galapagos NV's return on equity of 7.25%.

Mithra Pharmaceuticals SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Galapagos NV has an analysts' consensus of -- which suggests that it could grow by 17.59%. Given that Galapagos NV has higher upside potential than Mithra Pharmaceuticals SA, analysts believe Galapagos NV is more attractive than Mithra Pharmaceuticals SA.

Mithra Pharmaceuticals SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Galapagos NV has a beta of 0.229, suggesting its less volatile than the S&P 500 by 77.056%.

Mithra Pharmaceuticals SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galapagos NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mithra Pharmaceuticals SA pays -- of its earnings as a dividend. Galapagos NV pays out -- of its earnings as a dividend.

Mithra Pharmaceuticals SA quarterly revenues are --, which are smaller than Galapagos NV quarterly revenues of $65.8M. Mithra Pharmaceuticals SA's net income of -- is lower than Galapagos NV's net income of -$55.5M. Notably, Mithra Pharmaceuticals SA's price-to-earnings ratio is -- while Galapagos NV's PE ratio is 7.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mithra Pharmaceuticals SA is -- versus 6.23x for Galapagos NV. Usually stocks with elevated PS ratios are considered overvalued.

MDxHealth SA has a net margin of -- compared to Mithra Pharmaceuticals SA's net margin of -47.99%. Mithra Pharmaceuticals SA's return on equity of -- beat MDxHealth SA's return on equity of -650.14%.

Mithra Pharmaceuticals SA has a consensus price target of --, signalling downside risk potential of --. On the other hand MDxHealth SA has an analysts' consensus of -- which suggests that it could grow by 166.08%. Given that MDxHealth SA has higher upside potential than Mithra Pharmaceuticals SA, analysts believe MDxHealth SA is more attractive than Mithra Pharmaceuticals SA.

Mithra Pharmaceuticals SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MDxHealth SA has a beta of -390,599.621, suggesting its less volatile than the S&P 500 by 39060062.135%.

Mithra Pharmaceuticals SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MDxHealth SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mithra Pharmaceuticals SA pays -- of its earnings as a dividend. MDxHealth SA pays out -- of its earnings as a dividend.

Mithra Pharmaceuticals SA quarterly revenues are --, which are smaller than MDxHealth SA quarterly revenues of $23.3M. Mithra Pharmaceuticals SA's net income of -- is lower than MDxHealth SA's net income of -$11.2M. Notably, Mithra Pharmaceuticals SA's price-to-earnings ratio is -- while MDxHealth SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mithra Pharmaceuticals SA is -- versus 0.87x for MDxHealth SA. Usually stocks with elevated PS ratios are considered overvalued.

Nyxoah SA has a net margin of -- compared to Mithra Pharmaceuticals SA's net margin of -1347.39%. Mithra Pharmaceuticals SA's return on equity of -- beat Nyxoah SA's return on equity of -51.1%.

Mithra Pharmaceuticals SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Nyxoah SA has an analysts' consensus of -- which suggests that it could grow by 95.91%. Given that Nyxoah SA has higher upside potential than Mithra Pharmaceuticals SA, analysts believe Nyxoah SA is more attractive than Mithra Pharmaceuticals SA.

Mithra Pharmaceuticals SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nyxoah SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Mithra Pharmaceuticals SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nyxoah SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mithra Pharmaceuticals SA pays -- of its earnings as a dividend. Nyxoah SA pays out -- of its earnings as a dividend.

Mithra Pharmaceuticals SA quarterly revenues are --, which are smaller than Nyxoah SA quarterly revenues of $1.4M. Mithra Pharmaceuticals SA's net income of -- is lower than Nyxoah SA's net income of -$18.8M. Notably, Mithra Pharmaceuticals SA's price-to-earnings ratio is -- while Nyxoah SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mithra Pharmaceuticals SA is -- versus 44.46x for Nyxoah SA. Usually stocks with elevated PS ratios are considered overvalued.

UCB SA has a net margin of -- compared to Mithra Pharmaceuticals SA's net margin of --. Mithra Pharmaceuticals SA's return on equity of -- beat UCB SA's return on equity of 2.64%.

Mithra Pharmaceuticals SA has a consensus price target of --, signalling downside risk potential of --. On the other hand UCB SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Mithra Pharmaceuticals SA has higher upside potential than UCB SA, analysts believe Mithra Pharmaceuticals SA is more attractive than UCB SA.

Mithra Pharmaceuticals SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison UCB SA has a beta of 0.733, suggesting its less volatile than the S&P 500 by 26.695%.

Mithra Pharmaceuticals SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UCB SA offers a yield of 0.75% to investors and pays a quarterly dividend of $0.72 per share. Mithra Pharmaceuticals SA pays -- of its earnings as a dividend. UCB SA pays out 73.47% of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Mithra Pharmaceuticals SA quarterly revenues are --, which are smaller than UCB SA quarterly revenues of --. Mithra Pharmaceuticals SA's net income of -- is lower than UCB SA's net income of --. Notably, Mithra Pharmaceuticals SA's price-to-earnings ratio is -- while UCB SA's PE ratio is 148.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mithra Pharmaceuticals SA is -- versus 6.48x for UCB SA. Usually stocks with elevated PS ratios are considered overvalued.